Random Records

Note: COSMIC-3D provides structural perspectives on cancer genetics for drug discovery (doi: 10.1038/s41588-018-0214-9) • COSMIC-3D is designed to enable greater understanding of the functional impact of mutations, generate new hypotheses on which mutations are cancer drivers and provide new opportunities for addressing these mutations pharmaceutically. • genetics, structural proteomics and drug development can be best described as ‘mutation-guided drug design’. • there remains much scope for expansion of the repertoire of precision therapeutic drugs targeting these mutations. • Both cancer genomic and protein structural data sources are individually great assets for scientists working in the field of oncology drug discovery. • COSMIC-3D currently maps cancer variant data for nearly 9,300 genes to nearly 37,000 protein structures, covering 390 key genes from the Cancer Gene Census. • The structure viewer displays the protein structure and small-molecule ligands,

Note for: Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas (doi: 10.1016/j.celrep.2018.03.076 )   The Cancer Genome Atlas (TCGA) Pan-Cancer analysis of DNA damage repair (DDR) deficiency in cancer. using integrative genomic and molecular analyses the data from cancer (33 cancer), basically focus on DDR. HR and directed repair are the most frequency altered.  We systematically analyzed somatic alterations to provide a comprehensive view of DDR deficiency across 33 cancer types. DDR genes can be grouped into functional pathways defined by genetic, biochemical, and mechanistic criteria.  Type of damages; 1. DNA base damage -BER, NER and DR 2. Mismatch - MMR 3. DNA strand break - HR, NHEJ, FA, and TLS All of the major DDR pathways, with the exception of the FA pathway, have been identified in virtually all organisms. This reflects the universal need to counter the chemical instability of DNA and repair additional damage. Frequent TP53 somatic m

Note for: Roles of eukaryotic topoisomerases in transcription, replication and genomic stability (doi: 10.1038/nrm.2016.111) Their catalytic intermediates, the topoisomerase cleavage complexes (TOPcc), are therapeutic targets of various anticancer drugs. E ngage specific repair pathways, such as those mediated by tyrosyl-DNA phosphodiesterase 1 (TDP1) and TDP2 and by endonucleases (MRE11, XPF–ERCC1 and MUS81). Aim of this paper; 1.review roles of Topo in mediating chromatin dynamics, transcription, replication, DNA damage repair and genome stability. 2.dysregulation of topoisomerase -- neurodegenerative disease, immune disorder and cancer DNA topoisomerase; 1.solve DNA topological problems 2.occur during replication and transcription Important in both nuclear and mitochondrial genomes. Each isoform of topoisomerase has shared and specialized roles. Top2a and Top2b -- relax negatively supercoiled DNA Top2a requires for chromosome segregation (dividing

Note from  Annual Meeting of the Thai Society for Biotechnology and International Conference (TSB 2018) I enjoy the tissue engineering part at the most. Tissue engineering preparation 1. facing the issue production inconsistency - vary lot by lot 2. try to use robot arm to solve the issue, however, there are some steps which the robot arm could not replace the human labor. The robot arm in some extent is much slower and less delicate in term of movement than human labor. 3. learning that Thailand so far could not produce the robot arm + clean room platform - KMUTT (Bio-processing unit - pilot plant) makes the collaboration with Japan -> to make this comes to reality -- though Thai side could not produce the robot arm, at least, the team can make the software to control the arm as well as to design the workflow. 4. There are many things that all the physicians mentioned, especially when applying to the patients; - iPS technology was awarded by the Nobel prize in the year of

Note for: Maximizing computational tools for successful drug discovery (doi: 10.1517/17460441.2015.1016497) Selecting the appropriate computational tools is dependent on the goal of the drug discovery project - for instance - 1. understanding the SAR of a compound series 2. synthesizing/optimizing novel leads 3. understanding the binding modality for compounds of interest 4. screening for novel compounds with desired bioactivity 5. identifying potential toxicity in compounds 6. designing multi-target inhibitors 7. predicting the side effects of drugs Aim of this review: this editorial will briefly touch upon several key steps in the drug discovery process and their associated tools in the context of trying to cover most (if not all) of these essential topics in drug discovery. we also confer known or potential opportunities and problems that researchers may need to be aware of in their drug discovery endeavors. Despite the seemingly large chemical l